Figure 2.

Proportion of patients who had an Investigator’s Global Assessment (IGA) score of 0 or 1 and achieved a reduction of ≥ 2 points in their IGA score from baseline at week 16 (primary endpoint). *P < 0·001 for difference (95% confidence interval).